Cardiovascular Systems Inc. (CSII) announced Monday that it presented 30-day data from its ORBIT II study of severely calcified coronary lesions at the 2013 American College of Cardiology conference in San Francisco. The results demonstrated that CSI's technology produced clinical outcomes that exceeded the trial's two primary endpoints by a significant margin.
Cardiovascular Systems has been rising since the open of trade Monday and is now up 1.40 at $17.90. The stock has climbed above a month and a half long range and has set a new high for the year.
For comments and feedback: editorial@rttnews.com